← All trials
NCT03304210
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 25, 2017
- Primary completion
- Sep 21, 2020
- Completion date
- Dec 21, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 20
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ghent UniversityLead sponsor
- Ghent UniversityOverall official - principal investigator
- University of ParisCollaborator
- Kom Op Tegen KankerCollaborator
- Ghent UniversityCollaborator
- University of LausanneCollaborator
- IRCCS CANDIOLOCollaborator
- University of TuebingenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.